A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 344 participants.

Also called NCT07481981

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 344 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07481981
  • EU CT 2026-525265-48-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Israel, Japan, New Zealand, South Korea, Taiwan (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07481981. Randomized; double masking; primary purpose treatment. Start 2026-07-21 (actual); primary completion 2028-12-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
Acronym
PALM-PAH
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Treprostinil Palmitil Inhalation Powder
Intervention (Drug)
Placebo
Lead sponsor
Insmed Incorporated (class: industry)

Record details

Record id
cardio:ct-nct07481981
Content hash
48474aba12714474ec9f738a8b2796fbc4f46a4baf3ca95dd5f4a57ef20cdb97